Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

RIGL holding history

Rigel Pharmaceuticals Inc in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

RIGL overviewAll 13F holders of RIGLFull Q2 2026 holdings

Shares (Q2 2026)
122,954
Value
$4.81M
% of portfolio
<0.1%
Quarters held
20
Since Q1 2021
Holdings of RIGL by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026122,954$4.81M<0.1%+72,878+145.5%AddedHolders
Q1 202650,076$1.35M<0.1%+3,638+7.8%AddedHolders
Q4 202546,438$1.99M<0.1%−54,159−53.8%ReducedHolders
Q3 2025100,597$2.85M<0.1%+32,541+47.8%AddedHolders
Q2 202568,056$1.27M<0.1%+21,341+45.7%AddedHolders
Q1 202546,715$840.4K<0.1%+33,048+241.8%AddedHolders
Q4 202413,667$229.9K<0.1%+4,491+48.9%AddedHolders
Q3 20249,176$148.5K<0.1%+9,176NewHolders
Q2 20240$00.0%−17,916−100.0%Sold outConverted for a 1-for-10 splitHolders
Q1 2024179,164$265.2K<0.1%+27,801+18.4%AddedHolders
Q4 2023151,363$219.5K<0.1%+73,191+93.6%AddedHolders
Q3 202378,172$84.4K<0.1%−36,041−31.6%ReducedHolders
Q2 2023114,213$147.3K<0.1%+42,162+58.5%AddedHolders
Q1 202372,051$95.1K<0.1%+49,014+212.8%AddedHolders
Q4 202223,037$34.6K<0.1%+23,037NewHolders
Q3 20220$00.0%−590,858−100.0%Sold outHolders
Q2 2022590,858$668.0K<0.1%+293,803+98.9%AddedHolders
Q1 2022297,055$888.0K<0.1%−123,930−29.4%ReducedHolders
Q4 2021420,985$1.11M<0.1%+405,153+2,559.1%AddedHolders
Q3 202115,832$57.0K<0.1%−27,987−63.9%ReducedHolders
Q2 202143,819$191.0K<0.1%−270,930−86.1%ReducedHolders
Q1 2021314,749$1.08M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.